BIOTECHNOLOGY VALUE FUND L P
CIK 918923 · last filed 2026-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.66B
Companies
22
Total Filings
47
Lifetime Open-Market Net
-$1.54B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLTX | Director | 8,302,735 | $18.71 | $155.34M | -$1.63B | 2 | 2026-04-02 |
| OLMA | Director | 2,990,983 | $11.62 | $34.76M | $0 | 1 | 2024-12-04 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 1,794,218 | $5.38 | $9.65M | -$143.00M | 1 | 2024-10-31 | |
| KYMR | Director | 294,632 | $106.16 | $31.28M | $1.41M | 3 | 2024-06-28 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 548,938 | $2.65 | $1.45M | $203.21M | 2 | 2023-11-17 |
| RAIN | 1,076,314 | $1.32 | $1.42M | $99.26M | 2 | 2021-09-15 | |
| XOMAP | 10%+ Owner | 1,960,384 | $24.98 | $48.97M | -$249.99M | 1 | 2021-04-02 |
| Merus N.V. (MRUS) Delisted | 427,377 | $90.00 | $38.46M | $57.50M | 1 | 2021-03-18 | |
| XOMA | 10%+ Owner | 171,336 | $40.17 | $6.88M | $15.59M | 3 | 2020-09-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 3,078,989 | $38.00 | $117.00M | $14.60M | 1 | 2019-12-26 |
| CYTK | 2,811,818 | $79.45 | $223.40M | $22.60M | 1 | 2019-12-12 | |
| Calithera Biosciences, Inc. (CALA) Delisted | 32,371 | $0.00 | $10 | $44.17M | 1 | 2019-10-31 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 1,167,191 | $0.04 | $52.2K | $47.24M | 3 | 2018-06-21 |
| XENE | 297,464 | $64.94 | $19.32M | $4.07M | 3 | 2017-08-16 | |
| PTN | 122,877 | $7.68 | $943.7K | -$2.14M | 1 | 2014-02-19 | |
| LGND | 3,299,569 | $296.28 | $977.60M | $6.20M | 8 | 2012-12-18 | |
| CAPS | 1,322 | $0.25 | $328 | $338.5K | 2 | 2011-07-28 | |
| FACT | 7,849,140 | $10.67 | $83.75M | $3.64M | 1 | 2010-02-09 | |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 16,062,944 | — | — | -$10.89M | 2 | 2009-12-24 | |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 1,098,392 | $15.50 | $17.03M | -$21.87M | 2 | 2009-08-10 | |
| NBIX | 5,905,447 | $182.83 | $1.08B | $1.80M | 3 | 2009-01-22 | |
| AVIGEN INC \DE (AVGN) Delisted | 8,279,715 | — | — | $584.3K | 1 | 2008-11-20 |
Recent Filings · Page 3 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-16 | XENE | Buy (P) | +421,414 | $1.10M | EDGAR |
| 2017-06-29 | XENE | Buy (P) | +598,227 | $2.39M | EDGAR |
| 2017-06-23 | XENE | Buy (P) | +142,877 | $571.5K | EDGAR |
| 2017-01-05 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +30,653 | $41.1K | EDGAR |
| 2016-12-02 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +1,409,758 | $1.67M | EDGAR |
| 2014-02-19 | PTN | Sell (S) | −1,835,796 | -$2.14M | EDGAR |
| 2012-12-18 | LGND | Buy (P) | +32,316 | $602.2K | EDGAR |
| 2012-12-10 | LGND | Buy (P) | +300,600 | $5.39M | EDGAR |
| 2011-10-20 | LGND | Buy (P) | +84,600 | $1.18M | EDGAR |
| 2011-10-14 | LGND | Buy (P) | +452,118 | $6.17M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.